{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T02:02:42Z","timestamp":1779847362553,"version":"3.53.1"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T00:00:00Z","timestamp":1775865600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T00:00:00Z","timestamp":1779840000000},"content-version":"vor","delay-in-days":46,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Urol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>To compare the geometric consistency, dosimetric performance, and early clinical outcomes of the BioProtect balloon spacer versus the Barrigel hydrogel spacer in patients receiving proton therapy for prostate cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective study analyzed 50 prostate cancer patients treated with proton therapy: 25 with BioProtect and 25 with Barrigel. Anatomical displacement, rectal dose (V70\/V60\/V50), rectal wall infiltration (RWI), and early gastrointestinal (GI) toxicity were assessed. Two treatment plans per patient (prostate-only and whole-pelvis) were generated using identical optimization workflows. Geometric and dosimetric comparisons were performed using t-tests, and correlations between anatomy and dose were evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      BioProtect achieved greater midgland (18.28\u00a0mm vs. 14.52\u00a0mm,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.01) and apical (12.8\u00a0mm vs. 8.3\u00a0mm,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) separation. Prostate-only plans with BioProtect showed significantly lower rectal V60 (2.02% vs. 6.69%) and V50 (4.28% vs. 10.16%) (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.01). Whole-pelvis plans showed V70\/V60\/V50 reductions of 72.8%, 66.1%, and 66.7%, respectively (all\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.01). No RWI events occurred in the BioProtect arm, compared to three with Barrigel. Acute grade\u2009\u2265\u20092 GI toxicity was observed in 0% of BioProtect vs. 17.4% of Barrigel patients at 3 months.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>BioProtect demonstrated superior and more consistent rectal sparing in proton therapy compared to Barrigel. The fixed geometry balloon design yielded enhanced separation, reduced rectal dose, and fewer early GI toxicities. These findings suggest an dosimetric and clinical advantage of BioProtect in the proton therapy setting.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12894-026-02139-9","type":"journal-article","created":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T01:38:04Z","timestamp":1775871484000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comprehensive comparison of Bioprotect balloon and Barrigel hydrogel rectal spacers in proton therapy for prostate cancer"],"prefix":"10.1186","volume":"26","author":[{"given":"Joey","family":"Arnold","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,11]]},"reference":[{"key":"2139_CR1","doi-asserted-by":"publisher","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17\u201348. https:\/\/doi.org\/10.3322\/caac.21763.","DOI":"10.3322\/caac.21763"},{"issue":"3 Suppl","key":"2139_CR2","doi-asserted-by":"publisher","first-page":"S123","DOI":"10.1016\/j.ijrobp.2009.03.078","volume":"76","author":"JM Michalski","year":"2010","unstructured":"Michalski JM, Gay H, Jackson A, Tucker SL, Deasy JO. Radiation dose-volume effects in radiation-induced rectal injury. Int J Radiat Oncol Biol Phys. 2010;76(3 Suppl):S123\u2013129. https:\/\/doi.org\/10.1016\/j.ijrobp.2009.03.078.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"2139_CR3","doi-asserted-by":"publisher","first-page":"22","DOI":"10.14338\/IJPT.13-00003.1","volume":"1","author":"S Rana","year":"2014","unstructured":"Rana S, Cheng C, Zheng Y, et al. Proton Therapy vs. VMAT for Prostate Cancer: A Treatment Planning Study. Int J Part Ther. 2014;1(1):22\u201333. https:\/\/doi.org\/10.14338\/IJPT.13-00003.1.","journal-title":"Int J Part Ther"},{"issue":"2","key":"2139_CR4","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.ijrobp.2024.08.012","volume":"120","author":"JA Efstathiou","year":"2024","unstructured":"Efstathiou JA, Yeap BY, Michalski JM, et al. Prostate Advanced Radiation Technologies Investigating Quality of Life (PARTIQoL): Phase III Randomized Clinical Trial of Proton Therapy vs. IMRT for Localized Prostate Cancer. Int J Radiat Oncol Biol Phys. 2024;120(2):S1. https:\/\/doi.org\/10.1016\/j.ijrobp.2024.08.012.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2139_CR5","doi-asserted-by":"publisher","first-page":"100111","DOI":"10.1016\/j.ijpt.2024.100111","volume":"13","author":"VR Dhere","year":"2024","unstructured":"Dhere VR, Goyal S, Zhou J, et al. Impact of Rectal Spacer on Toxicity Reduction in Men Treated With Proton Versus Photon Therapy. Int J Part Ther. 2024;13:100111. https:\/\/doi.org\/10.1016\/j.ijpt.2024.100111.","journal-title":"Int J Part Ther"},{"issue":"3","key":"2139_CR6","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.ijrobp.2020.07.476","volume":"108","author":"MJ Zelefsky","year":"2020","unstructured":"Zelefsky MJ, et al. Long-term outcomes of proton beam therapy for prostate cancer with rectal spacers. Int J Radiat Oncol Biol Phys. 2020;108(3):600\u20137.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2139_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.prro.2025.01.009","author":"J Lippens","year":"2025","unstructured":"Lippens J, Willems L, Boychak O, Pinkawa M. Implantable Rectal Spacers in Prostate Cancer Radiation Therapy: A Systematic Review. Pract Radiat Oncol. 2025. https:\/\/doi.org\/10.1016\/j.prro.2025.01.009.","journal-title":"Pract Radiat Oncol"},{"issue":"3","key":"2139_CR8","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.prro.2016.10.004","volume":"7","author":"BW Fischer-Valuck","year":"2017","unstructured":"Fischer-Valuck BW, Chundury A, Gay H, Bosch W, Michalski J. Hydrogel spacer distribution within the perirectal space in patients undergoing radiotherapy for prostate cancer: Impact of spacer symmetry on rectal dose reduction and the clinical consequences of hydrogel infiltration into the rectal wall. Pract Radiat Oncol. 2017;7(3):195\u2013202. https:\/\/doi.org\/10.1016\/j.prro.2016.10.004.","journal-title":"Pract Radiat Oncol"},{"issue":"3","key":"2139_CR9","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.prro.2016.10.004","volume":"7","author":"M Pinkawa","year":"2017","unstructured":"Pinkawa M, et al. Spacer symmetry and rectal dose reduction in prostate cancer radiotherapy. Pract Radiat Oncol. 2017;7(3):195\u2013202.","journal-title":"Pract Radiat Oncol"},{"issue":"4","key":"2139_CR10","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1001\/jamaoncol.2023.220095","volume":"9","author":"NF Mariados","year":"2023","unstructured":"Mariados NF, Orio PF, Schiffman Z, et al. Hyaluronic Acid Spacer for Hypofractionated Prostate Radiation Therapy: A Randomized Clinical Trial. JAMA Oncol. 2023;9(4):534\u201341. https:\/\/doi.org\/10.1001\/jamaoncol.2023.220095.","journal-title":"JAMA Oncol"},{"issue":"6","key":"2139_CR11","doi-asserted-by":"publisher","first-page":"3385","DOI":"10.21873\/invivo.12637","volume":"35","author":"P Pepe","year":"2021","unstructured":"Pepe P, Tamburo M, Pennisi M, Marletta D, Marletta F. Clinical outcomes of hydrogel spacer injection SpaceOAR in men submitted to hypofractionated radiotherapy for prostate cancer. Vivo. 2021;35(6):3385\u20139. https:\/\/doi.org\/10.21873\/invivo.12637.","journal-title":"Vivo"},{"issue":"5","key":"2139_CR12","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1016\/j.ijrobp.2024.07.2145","volume":"120","author":"D Song","year":"2024","unstructured":"Song D, Dabkowski M, Costa P, et al. Prospective, Randomized Controlled Pivotal Trial of Biodegradable Balloon Rectal Spacer for Prostate Radiation Therapy. Int J Radiat Oncol Biol Phys. 2024;120(5):1410\u201320. https:\/\/doi.org\/10.1016\/j.ijrobp.2024.07.2145.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"10","key":"2139_CR13","doi-asserted-by":"publisher","first-page":"e14086","DOI":"10.1002\/acm2.14086","volume":"24","author":"M Kos","year":"2023","unstructured":"Kos M, Nurani R, Costa P, et al. Multicenter, dual fractionation scheme, single core lab comparison of rectal volume dose reduction following injection of two biodegradable perirectal spacers. J Appl Clin Med Phys. 2023;24(10):e14086. https:\/\/doi.org\/10.1002\/acm2.14086.","journal-title":"J Appl Clin Med Phys"},{"key":"2139_CR14","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.urology.2023.09.016","volume":"183","author":"AM Fernandez","year":"2024","unstructured":"Fernandez AM, Jones CP, Patel HV, et al. Real-World Complications of the SpaceOAR Hydrogel Spacer: A Review of the Manufacturer and User Facility Device Experience Database. Urology. 2024;183:157\u201362. https:\/\/doi.org\/10.1016\/j.urology.2023.09.016.","journal-title":"Urology"},{"issue":"2","key":"2139_CR15","doi-asserted-by":"publisher","first-page":"166","DOI":"10.4081\/aiua.2022.2.166","volume":"94","author":"P Pepe","year":"2022","unstructured":"Pepe P, Tamburo M, Panella P, Pepe L, Marletta G, Pennisi M, Marletta F. Erectile dysfunction following hydrogel injection and hypofractionated radiotherapy for prostate cancer: Our experience in 56 cases. Arch Ital Urol Androl. 2022;94(2):166\u20138. https:\/\/doi.org\/10.4081\/aiua.2022.2.166.","journal-title":"Arch Ital Urol Androl"},{"issue":"17","key":"2139_CR16","doi-asserted-by":"publisher","first-page":"9414","DOI":"10.3390\/app15179414","volume":"15","author":"S Oliveira","year":"2025","unstructured":"Oliveira S, Fernandes R, Baylina P, Santos J, Vieira G. The impact of a rectal spacer in VMAT dosimetry in the treatment of prostate cancer. Appl Sci. 2025;15(17):9414. https:\/\/doi.org\/10.3390\/app15179414.","journal-title":"Appl Sci"}],"container-title":["BMC Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12894-026-02139-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-026-02139-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-026-02139-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T01:13:49Z","timestamp":1779844429000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12894-026-02139-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,11]]},"references-count":16,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2139"],"URL":"https:\/\/doi.org\/10.1186\/s12894-026-02139-9","relation":{},"ISSN":["1471-2490"],"issn-type":[{"value":"1471-2490","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,11]]},"assertion":[{"value":"13 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This retrospective study utilized fully de-identified patient data obtained from routine clinical care. In accordance with the U.S. Department of Health and Human Services regulations (45 CFR 46), research involving the analysis of de-identified data does not constitute human subjects research and is therefore exempt from Institutional Review Board (IRB) oversight.The Oklahoma Proton Center does not maintain a local IRB; however, all study procedures were conducted in accordance with applicable federal guidelines and institutional policies governing the use of de-identified data.As this study involved only retrospective, de-identified data, the requirement for informed consent was waived.All methods were carried out in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"127"}}